Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
ADELAIDE, AUS, Sep 04, 2020 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner Avance Clinical is pleased to share the news that its client Immunic Therapeutics has announced dosing of the first healthy volunteer in the company's phase 1 clinical program of IMU-856, an novel treatment for patients suffering from gastrointestinal diseases, including diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease.
Immunic Therapeutics (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.
According to the public announcement released by Immunic Therapeutics on 20 August 2020:
> IMU-856, an orally available, small molecule modulator, serves as a transcriptional regulator of intestinal barrier function. Based on preclinical data, the compound appears to represent a novel and potentially paradigm-shifting approach to the treatment of gastrointestinal diseases by potentially restoring intestinal barrier function while maintaining immunocompetency.
> Immunic's Australian subsidiary, Immunic Australia Pty Ltd., received approval from the Bellberry Human Research Ethics Committee in Australia to conduct a phase 1 clinical trial of IMU-856 under the Clinical Trial Notification (CTN) scheme of the Australian Therapeutic Goods Administration (TGA). The phase 1 clinical program includes single and multiple ascending dose parts in healthy volunteers. Subsequently, Immunic also plans to extend this program to assess biomarker, safety and drug trough levels in patients with diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease.
Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, noted, "Current treatments for many gastrointestinal conditions focus on inhibiting inflammation and do not directly address impaired intestinal barrier function. In contrast, IMU-856 appears to have a unique targeted ability to strengthen and thereby normalize this function, potentially avoiding the bacterial triggers which can occur when the intestinal barrier is impaired. Moreover, because this approach appears to avoid any detrimental effects on the immune system, we believe that IMU-856 has the potential to change the treatment paradigm for gastrointestinal diseases."
Avance Clinical Chief Scientific Officer Gabriel Kremmidiotis PhD, BSC Hon said, "We consider ourselves fortunate to be working with Immunic on this exciting project. IMU-856 is the second compound that Immunic has selected Avance Clinical as their CRO. Our engagement in these projects has been from early planning, study design, preparation of the investigator brochures and clinical trial protocols. Working with the Immunic team and the Bellberry Human Research Ethics Committee, we have been able to design clinical trials which include careful data informed adaptive elements aimed at expediting the transition of these promising products from healthy volunteers to the patient populations."
See full announcement here: https://tinyurl.com/y5rvh7fa
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORrt; and IMU-856 targets the restoration of the intestinal barrier function. On August 2, 2020, Immunic announced positive top-line results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance, indicating activity for IMU-838 in this indication. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit: www.imux.com.
About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world. Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit http://www.avancecro.com for more information. Other benefits include: 1. The Government R&D grant means up to 43.5% rebate on clinical trial spend 2. Telehealth pivot during COVID-19 pandemic - speed and continuity 3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks 4. No IND required for clinical trials 5. Full GMP material is not mandated for Phase I clinical trials 6. Established clinical trial environment with world-class Investigators and sites 7. Established healthy subject databases and specialized patient populations 8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care 9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research 10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact: media@avancecro.com Chris Thompson
Source: Avance Clinical Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
![NTT DOCOMO](http://www.jcnnewswire.com/image/toppage/Docomo_Top.jpg) DOCOMO and NTT Com Jointly Demonstrate Practicality of DOCOMO's New Multi-platform Cloud-rendering Technology Jul 26, 2024 17:05 JST
| ![Tanaka Holdings Co., Ltd.](http://www.jcnnewswire.com/image/toppage/Tanaka_Logo_2s.jpg) TANAKA Precious Metals Provided Award Items and Ceremony Souvenirs for the International Friendly Matches of the Japan Men's National Blind Football Team at the "DAICEL Blind Football Japan Cup 2024 in Osaka" on July 7 Jul 26, 2024 03:00 JST
| ![Eisai](http://www.jcnnewswire.com/image/toppage/eisai45.jpg) Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration Jul 25, 2024 10:30 JST
| ![Hitachi, Ltd.](http://www.jcnnewswire.com/image/toppage/hitachi.jpg) Hitachi Awarded Largest Contract in Singapore to Supply 450 Lifts at HDB Blocks Jul 24, 2024 16:27 JST
| ![Hitachi, Ltd.](http://www.jcnnewswire.com/image/toppage/hitachi.jpg) Hitachi to Announce Capital Reorganization of Air Conditioning Joint Venture Jul 24, 2024 15:02 JST
| ![Eisai](http://www.jcnnewswire.com/image/toppage/eisai45.jpg) Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 Jul 23, 2024 20:23 JST
| ![Fujitsu Ltd](http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg) Toyota Material Handling Japan and Fujitsu launch Japan's first service for evaluating forklift safety in the cloud using AI Jul 23, 2024 11:26 JST
| ![Toyota Motor Corporation](http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg) AEON and CJPT working to resolve logistics industry issues and achieve carbon neutrality at AEON Fukuoka XD Jul 22, 2024 13:52 JST
| ![Toyota Motor Corporation](http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg) Rovanpera and Ogier score another TOYOTA GAZOO Racing one-two Jul 22, 2024 12:30 JST
| ![Honda Motor Co, Ltd](http://www.jcnnewswire.com/image/toppage/honda.gif) Team HRC with Japan Post Wins 45th Suzuka 8 Hours Endurance Road Race Jul 22, 2024 11:33 JST
| ![Honda Motor Co, Ltd](http://www.jcnnewswire.com/image/toppage/honda.gif) Honda to Hold its Official e-Motorsports Event, "Honda Racing eMS 2024" Jul 19, 2024 20:04 JST
| ![Mitsubishi Heavy Industries, Ltd.](http://www.jcnnewswire.com/image/toppage/MHI_newT.jpg) MHI America Acquires Three Utility-Scale Solar Power Projects in Pennsylvania, Advancing the Company's Energy Transition Strategy Jul 19, 2024 19:04 JST
| ![JCB](http://www.jcnnewswire.com/image/toppage/JCB55.jpg) JCB and Worldline unveil a new whitepaper offering European merchants invaluable insights into facilitating seamless payments for international consumers Jul 19, 2024 12:00 JST
| ![Fujitsu Ltd](http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg) Fujitsu Chosen to Help Solving Social Issues Caused by Fake News Jul 19, 2024 11:30 JST
| ![Champion REIT](http://www.jcnnewswire.com/image/toppage/ChampionREIT1_Top.jpg) Champion REIT holds first 'ESG Week' Jul 18, 2024 20:14 JST
| ![Lexus International](http://www.jcnnewswire.com/image/toppage/Lexus_68.jpg) Lexus LBX Adds a New High Performance Variant, the LBX "MORIZO RR" Jul 18, 2024 17:25 JST
| ![NEC Corporation](http://www.jcnnewswire.com/image/toppage/NEC.62.jpg) VitalLife and Bumrungrad International Hospital in Thailand Launch NEC's FonesVisuas Test: First Major Deployment Outside Japan, Revolutionizing Disease Risk Prediction Jul 18, 2024 15:34 JST
| ![Fujitsu Ltd](http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg) Fujitsu publishes CHRO Roundtable Report 2024, summarizing the challenges and implications of the implementation of data-driven human capital management Jul 18, 2024 10:44 JST
| ![Fujitsu Ltd](http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg) Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship Jul 16, 2024 23:26 JST
| ![Mitsubishi Corporation](http://www.jcnnewswire.com/image/toppage/MC.68.jpg) Neste and Mitsubishi Corporation agree on strategic partnership to develop supply chains for renewable chemicals and plastics Jul 16, 2024 18:36 JST
|
More Latest Release >>
|